Literature DB >> 6113483

Comparative study of subcutaneous, intramuscular, and intravenous administration of human insulin.

D R Owens, M K Jones, T M Hayes, L G Heding, K G Alberti, P D Home, J M Burrin.   

Abstract

Human insulin derived from porcine insulin was given subcutaneously (s.c.), intramuscularly (i.m.), and intravenously (i.v.) to normal men. The dosage for all three routes was 0 . 075 IU/kg body weight. Diluting medium was administered by s.c. injection to obtain control values. Somatostatin (100 microgram/h) was given to inhibit pancreatic beta cell secretion. The plasma glucose responses to s.c. injection of this insulin into the anterior abdominal wall and to i.m. injection into the thigh were similar with respect to the extent, onset, and duration of effect. Plasma glucose fell from mean (+/- SE) pre-injection values of 4 . 3 +/- 0 . 15 and 4 . 4 +/- 0 . 27 mmol/l, to 3 . 06 +/- 0 . 25 and 2 . 98 +/- 0 . 16 mmol/l by 90 to 105 min for s.c. and i.m. studies, respectively, thereafter returning to mean basal level by 6 h after i.m. injection, but remaining about 0 . 5 mmol/l below basal level after s.c. injection. A much more sudden, but short-lived, hypoglycaemic response occurred after i.v. insulin, with plasma glucose failing from 4. 50 +/- 0 . 42 to 1 . 45 +/- 0 . 16 mmol/l by 25 min, returning to mean basal value after 3 1/2 h. The mean (+/- SE) peak insulin levels after s.c. and i.m. injection were 0 . 13 +/- 0 . 01 and 0 . 18 +/- 0 . 04 pmol/ml at 90 and 60 min, respectively. After i.v. injection the maximum plasma insulin concentration of 6 . 9 +/- 0 . 73 pmol/ml was seen at 2 min. No adverse side-effects were observed.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6113483     DOI: 10.1016/s0140-6736(81)90300-7

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  6 in total

Review 1.  Insulin injection technique.

Authors:  J Thow; P Home
Journal:  BMJ       Date:  1990-07-07

Review 2.  Human insulin. A review of its biological activity, pharmacokinetics and therapeutic use.

Authors:  R N Brogden; R C Heel
Journal:  Drugs       Date:  1987-09       Impact factor: 9.546

Review 3.  Pharmacokinetics of insulin. Implications for continuous subcutaneous insulin infusion therapy.

Authors:  E W Kraegen; D J Chisholm
Journal:  Clin Pharmacokinet       Date:  1985 Jul-Aug       Impact factor: 6.447

4.  Low subcutaneous degradation and slow absorption of insulin in insulin-dependent diabetic patients during continuous subcutaneous insulin infusion at basal rate.

Authors:  D J Chisholm; E W Kraegen; M J Hewett; S Furler
Journal:  Diabetologia       Date:  1984-08       Impact factor: 10.122

5.  Impact of injection sites for soluble insulin on glycaemic control in type 1 (insulin-dependent) diabetic patients treated with a multiple insulin injection regimen.

Authors:  J E Henriksen; M S Djurhuus; A Vaag; P Thye-Rønn; D Knudsen; O Hother-Nielsen; H Beck-Nielsen
Journal:  Diabetologia       Date:  1993-08       Impact factor: 10.122

6.  Drug delivery interfaces in the 21st century: from science fiction ideas to viable technologies.

Authors:  Beata Chertok; Matthew J Webber; Marc D Succi; Robert Langer
Journal:  Mol Pharm       Date:  2013-08-26       Impact factor: 4.939

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.